Home

Eaton Vance Ohio Municipal Income Trust (EVO)

3.6400
-0.0300 (-0.82%)

Eaton Vance Ohio Municipal Income Trust is a closed-end management investment company that primarily focuses on providing current income for investors through the acquisition and management of a diversified portfolio of municipal securities

These securities are predominantly issued by Ohio municipalities and are designed to generate tax-exempt income for investors. The Trust aims to offer a blend of capital appreciation and income through strategic investments, while also considering the potential impact of market interest rates and economic conditions on municipal debt. By focusing on Ohio-based issuers, the Trust seeks to capitalize on local market opportunities and provide value to its shareholders.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close3.670
Open3.620
Bid3.570
Ask3.760
Day's Range3.580 - 3.670
52 Week Range2.850 - 7.980
Volume29,161
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume53,423

News & Press Releases

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Ongoing strategic partnership advances joint pipeline in neurodegeneration research
Via ACCESS Newswire · March 4, 2025
Evotec Announces Change in Management Board
Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025
Via ACCESS Newswire · February 26, 2025
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy
Via ACCESS Newswire · January 22, 2025
Ingles Markets, Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 27, 2024
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases
Via ACCESSWIRE · December 11, 2024
Evotec Announces Change in Management Board
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024
Via ACCESSWIRE · November 29, 2024
Comment on Withdrawn Non-Binding Offer
HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQEVO)
Via ACCESSWIRE · November 22, 2024
Insights into Evotec's Upcoming Earningsbenzinga.com
Via Benzinga · November 5, 2024
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners
Via ACCESSWIRE · November 4, 2024
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology
Via ACCESSWIRE · October 22, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 22, 2024
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlookbenzinga.com
Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.
Via Benzinga · November 22, 2024
Intuit Issues Weak Forecast, Joins Reddit And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 22, 2024
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billionbenzinga.com
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.
Via Benzinga · November 15, 2024
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQEVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Via ACCESSWIRE · November 14, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 11, 2024
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Dealbenzinga.com
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company.
Via Benzinga · November 11, 2024
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 6, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 6, 2024
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions
Via ACCESSWIRE · November 5, 2024
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · November 4, 2024
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQEVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.
Via ACCESSWIRE · October 29, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · October 23, 2024
Why Is Evotec Stock Gaining Today?benzinga.com
Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.
Via Benzinga · October 23, 2024
Sherwin-Williams, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 7, 2024